MedTrace Logo

Dual Therapy With Boosted Darunavir + Dolutegravir

NCT02486133 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 269

Last updated 2023-11-29

No results posted yet for this study

Summary

A switch strategy to investigate whether a dual therapy with Ritonavir-boosted (RTV) Darunavir (DRV) + Dolutegravir (DTG) over 48 weeks is non-inferior to a continuous standard of care therapy with RTV-boosted DRV in combination with 2 Nucleosidic Reverse Transcriptase Inhibitors (NRTIs) in HIV patients, who are on a stable antiretroviral therapy (ART) with RTV-boosted DRV in combination with 2 NRTIs.

Conditions

  • HIV-Infection

Interventions

DRUG

Prezista

once daily

DRUG

Norvir

once daily

DRUG

Tivicay

once daily

DRUG

Truvada

once daily

DRUG

Kivexa

once daily

DRUG

Descovy

once daily

Sponsors & Collaborators

  • Technical University of Munich

    lead OTHER

Principal Investigators

  • Christoph Spinner, MD · Dep. of Medicine II & IZAR, Klinikum rechts der Isar der TUM

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2018-05-31
Completion
2018-05-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02486133 on ClinicalTrials.gov